We believe that laboratory data can be a powerful tool in managing the health of your patients, as well as supporting your organization to meet value-based care requirements.
As a trusted source of national laboratory patient data and result values, we have developed a reporting and analytical experience that helps you to identify high-risk patients and implement more effective clinical practices.
The interactive dashboards, available through Labcorp Link, go beyond data to offer intuitive on-demand management and reporting tools.
Here are some nationwide analytical snapshots to illustrate the breadth of insights:
Our Population Analysis reports help you evaluate specific patient populations to identify opportunities to improve the care they need. One such report includes disease screening and tracking using Labcorp laboratory results to identify COVID-19 prevalence and patterns of exposure.
Instead of a snapshot of a single moment in time, our Community Health reports provide you with real-world, geography-specific dynamic maps and reports to help you manage patient care. For example, our Community Antibiograms provide geographically specific information that can help your organization make data-driven decisions that may reduce antibiotic resistance in the community as well as help to prevent hospitalizations due to antibiotic resistant bacteria in community acquired infections.
Patients with diabetes or kidney disease are responsible for a significant percentage of healthcare costs, and require additional support to help them manage their chronic diseases. The Chronic Conditions report can help provide data to manage patients with these and other chronic conditions, identifying them and allowing providers to target gaps in care.
The right test for the right patient at the right time. The Lab Stewardship reports offer utilization reports for tests of interest based on national guidelines and best practices to identify ordering patterns, commonly mis-ordered tests and potential testing efficiencies within your organization.
Diabetes remains a major public health concern, with estimates that it affects 30 million people in the U.S. and cost the overall health system at least $327 billion annually. Labcorp's Diabetes report utilizes commonly performed diabetes testing to document the prevalence of the disease throughout the U.S. population. The report uses only Labcorp testing data, and provides diabetes and prediabetes information at the state level for 2019.
Urinary tract infections (UTI) caused by drug-resistant bacteria pose a serious threat to public health and can significantly increase healthcare costs.1 One major group of resistant bacteria includes members of the family Enterobacteriaceae (such as E. coli, Klebsiella species, and others) that produce extended-spectrum beta-lactamase (ESBL). ESBL provides resistance to multiple drugs, including penicillins, extended-spectrum cephalosporins, and monobactams.2 Using Labcorp data from antibiotic susceptibility testing, this snapshot shows the relative prevalence of community acquired UTIs caused by these ESBL-producing bacteria.